Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) subsidiary Shandong Zibo Xincat Pharmaceutical's cefuroxime axetil dispersible tablets passed China's generics consistency evaluation, according to a Monday filing with the Hong Kong Exchange.
The tablets are antibiotics indicated for the treatment of bacterial infections causing acute tonsillitis, pharyngitis and acute bacterial sinusitis, otitis media or middle ear infection, gonorrhea, among other infections, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments